Sanofi Cenrifki Wins EU CHMP Boost for Progressive MS
PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...
Sanofi
Advertisement
Regeneron & Sanofi Secure FDA Approval for Dupixent in Pediatric CSU
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
Sanofi Secures FDA Approval for Tzield in Young T1D
Paris, France – April 22, 2026 In a landmark advancement for pediatric endocrinology, Sanofi has secured U.S. FDA approval...
Regeneron Dupixent EU Approval Expands Pediatric CSU Care
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
Sanofi Rezurock Wins EU Approval for Chronic GvHD
PARIS, France, March 31, 2026 Sanofi has received European Commission approval for Rezurock® (belumosudil) for the treatment of chronic...
Advertisements
Sanofi Sarclisa SC Wins CHMP Nod for Myeloma Care
Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...
Dupixent Approved in Japan for Rare Skin Disease
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Sanofi Rilzabrutinib Wins Japan Orphan Status
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
CHMP Backs Acoziborole for Sleeping Sickness
KINSHASA / PARIS / GENEVA / AMSTERDAM – February 27, 2026 The European Medicines Agency’s Committee for Medicinal Products...
Sensorion Secures €60M to Advance Gene Therapies for Hearing Loss
MONTPELLIER, France | January 28, 2026 — Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, announced a...
Advertisement
